Executive Brief

News Report

The News: FDA accepts Afrezza for pediatric diabetes treatment.
Clinical Win: First needle-free insulin option for children aged 4 and older.
Target Specialty: Endocrinology

Key Data at a Glance

PDUFA Target Date: May 29, 2026
Trial Enrollment: 230 children aged 4-17
HbA1c Change: 0.435% in primary analysis

The FDA has accepted MannKind's supplemental Biologics License Application (sBLA) for Afrezza, an inhaled insulin therapy, for use in children and adolescents aged 4 to 17 with type 1 and type 2 diabetes. This marks a significant regulatory milestone, with a Prescription Drug User Fee Act (PDUFA) target action date set for May 29, 2026, potentially offering a needle-free alternative for young patients.

Clinical Context

Diabetes is a chronic condition characterized by high blood glucose levels due to insufficient insulin production or ineffective insulin use. The World Health Organization (WHO) reports that the prevalence of diabetes has risen dramatically, affecting over 830 million people globally as of 2022, with a notable increase in pediatric cases. Traditional insulin therapies often involve multiple daily injections, which can be burdensome and distressing for young patients and their families. Afrezza, a rapid-acting inhaled insulin, was initially approved for adults in 2014 and has been shown to provide a non-invasive option for managing blood glucose levels. The upcoming FDA decision on its use in pediatric populations aims to address the need for more child-friendly diabetes management solutions.

Key Findings

The FDA's acceptance of the sBLA for Afrezza indicates a potential expansion of its use to children and adolescents aged 4 to 17 with diabetes [6].

The pivotal INHALE-1 trial enrolled 230 participants aged 4-17, predominantly with type 1 diabetes (98%), and assessed the safety and efficacy of Afrezza compared to traditional rapid-acting insulin [8].

In the primary analysis, the trial showed that the change in HbA1c was 0.435% between groups, exceeding the noninferiority margin of 0.4% [8].

The modified intent-to-treat analysis, which excluded one nonadherent participant, indicated a difference of 0.370%, demonstrating that Afrezza can be a viable alternative [8].

No clinically significant changes in lung function were observed, and treatment satisfaction was reported to be higher in the Afrezza group [8].

What This Means for Clinical Practice

The FDA's acceptance of Afrezza for pediatric use could transform diabetes management for young patients. Clinicians treating children with diabetes will now have the option of prescribing a needle-free insulin, which may enhance adherence and improve the quality of life for families who struggle with the daily burden of injections. The inhaled delivery system allows for rapid absorption and may be particularly beneficial for needle-averse patients. As the FDA decision approaches, healthcare providers should prepare to discuss this new option with families, emphasizing the importance of monitoring and managing diabetes effectively in young populations. How this will integrate into current treatment protocols and guidelines remains to be seen, but it represents a promising shift in pediatric diabetes care.

Clinical Perspective

Workflow: Clinicians should prepare to discuss Afrezza as a treatment option for pediatric patients with diabetes, emphasizing its needle-free delivery.

Economics: The potential for improved adherence with Afrezza may reduce overall treatment costs associated with diabetes complications.

Patient Outcomes: Enhanced treatment options like Afrezza could lead to better glycemic control and quality of life for pediatric patients.

Dr. Amit Desai, Endocrinology

FDA Accepts Afrezza for Pediatric Diabetes: First Needle-Free Insulin for Ages 4 and Up

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Teplizumab for Type 1 Diabetes: Expanded Indication for Ages 1 and Above

FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Ages 4-17

FDA Approves Foundayo for Obesity: New Oral GLP-1 Option

Verified HCP Portal